Tirzepatide and Cancer Risk: What the Current Evidence Shows

What the SURMOUNT trials and regulatory reviews actually found

The SURMOUNT clinical programme, which formed the basis for tirzepatide's UK licence approval, involved thousands of adults across its trials — SURMOUNT-1 alone randomised 2,539 participants over 72 weeks. The SURMOUNT-1 paper, published in the New England Journal of Medicine, reported weight outcomes extensively; on cancer, the trial data did not reveal a statistically significant increase in human cancer incidence compared with placebo across the programme. That is the headline finding. It does not mean the question is closed, it means the evidence available so far does not support alarm, while justifying continued vigilance.

Regulators approached the thyroid question specifically. In rodent studies conducted at doses far exceeding clinical levels, GLP-1 receptor agonists as a class produced C-cell hyperplasia and, in some cases, medullary thyroid tumours. Tirzepatide is a dual GIP and GLP-1 receptor agonist, so it shares that class signal. The MHRA, alongside the European Medicines Agency, reviewed this data before granting the UK licence and concluded the human relevance remains uncertain, partly because rodent thyroid physiology differs meaningfully from human thyroid physiology. The NHS medicines page for tirzepatide reflects this: thyroid cancer is listed as a possible side effect to be aware of, not as a confirmed risk at therapeutic doses. The precautionary contraindication for people with medullary thyroid carcinoma or MEN2 history remains firm regardless, because even an uncertain signal warrants that caution in high-risk individuals.

It is also worth noting that the populations most likely to use tirzepatide (adults with obesity and metabolic conditions) already carry elevated baseline risks of certain cancers through mechanisms unrelated to any medicine. Disentangling drug effect from background risk in real-world data takes years of post-market surveillance, which is why tirzepatide carries a Black Triangle (▼) designation in the UK, signalling that the MHRA is actively collecting and reviewing reports.

Thyroid cancer specifically: what the contraindication means in practice

The thyroid signal gets the most attention, so it is worth being precise. The concern is with medullary thyroid carcinoma, a relatively rare cancer that arises from parafollicular C-cells, the same cell type that showed hyperplasia in the rodent studies. It accounts for roughly 3–4% of all thyroid cancers. The far more common thyroid cancers (papillary and follicular) arise from different cell types and are not the subject of the class signal.

For most people, there is no established reason to expect tirzepatide to raise their personal thyroid cancer risk. The licensed contraindication is specific: a personal or family history of medullary thyroid carcinoma, or a diagnosis of Multiple Endocrine Neoplasia type 2 (MEN2), which creates a genetic predisposition to it. Anyone in either group should not take tirzepatide, full stop. This is covered in every clinical assessment before prescribing. A broader exploration of tirzepatide and thyroid cancer risk sets out the biology in more detail if that specific question is what brought you here.

Outside those contraindicated groups, ongoing monitoring is the practical answer. If you develop a new lump in your neck, persistent hoarseness, or trouble swallowing while on treatment, tell a clinician. These symptoms warrant investigation regardless of whether you are on tirzepatide, and your prescriber should know.

When to get medical help (and how to report a concern

Most side effects on tirzepatide are gastrointestinal) nausea, reflux, loose stools, and they are covered in detail on the full risks and side-effects page. If you want a fuller picture of how tirzepatide's side effects relate to cancer specifically, that page walks through what is known and what remains under investigation. Cancer-related concerns sit in a different category: slower to develop, harder to attribute, and requiring clinical judgement rather than self-management. The practical guidance is straightforward.

Seek medical advice promptly if you notice: a lump or swelling in your neck that is new or growing; persistent hoarseness or a voice change lasting more than a few weeks; difficulty swallowing that does not resolve; or any symptom that feels unusual and new since starting treatment. None of these are common experiences on tirzepatide, and all of them have many causes other than cancer, but they should be assessed, not waited out.

The MHRA runs the Yellow Card scheme for reporting suspected side effects from medicines, including suspected cancer events. Patients can report directly; you do not need to go through a doctor first. These reports contribute to the post-market safety database that informs future regulatory decisions. If you have a concern about something you have experienced on tirzepatide, Yellow Card is the right place to record it.

Our prescribers discuss cancer-related contraindications and any personal history that might be relevant as a routine part of the consultation, not as a formality, but because it genuinely shapes what treatment is appropriate. You can find out more about how the clinical team approaches these assessments on our clinical team page.

The broader picture: what ongoing surveillance is designed to catch

Tirzepatide has been available in the UK since 2023 and is dispensed in growing volumes through private and, increasingly, NHS channels. The Black Triangle designation means every prescriber is expected to report adverse events, and the MHRA reviews accumulating data on a rolling basis. This is how rare signals (signals too infrequent to appear in even a well-powered trial) get detected.

For most people reading this page, the honest summary is: the evidence to date is reassuring but not yet long-term. Tirzepatide is not old enough as a widely used weight-loss medicine for decade-scale epidemiology to exist. What we have is a well-characterised rodent signal in a specific cell type, a clear precautionary contraindication for the highest-risk group, and no confirmed human cancer cases attributed to the drug across its clinical programme. If you are specifically asking whether Mounjaro raises your cancer risk, our page on the Mounjaro cancer risk question addresses that directly alongside the broader side-effect context. The full side-effect profile of Mounjaro puts this in context alongside the risks that are better established and more frequently encountered.

If you are weighing up whether treatment is right for you, the conversation with a prescriber is the place to do it, particularly if you have any personal or family history that might be relevant. A general overview of Mounjaro as a treatment, including its licensed uses and how it works, is available on the Mounjaro information page. And if you are ready to have your circumstances reviewed by a clinician, starting a free consultation is the natural next step.